Targeting regulation of the tumour microenvironment induces apoptosis of breast cancer cells by an affinity hemoperfusion adsorbent
Source abstract
Abstract
The cytokine network of tumour microenvironment (TME) plays an important role in cancer growth and progression. The current work aims to provide a new strategy for cancer therapy based on the targeted regulation of cytokines in the TME. Here, heparin-coupled polyvinyl alcohol (PVA-H) microspheres have been developed as an adsorbent for selectively remove tumour-induced immunosuppressive cytokines, such as vascular endothelial growth factor (VEGF) and transforming growth factor-beta (TGF-β), but not tumour necrosis factor-alpha (TNF-α) which has an immune-stimulating effect and can inhibit tumour growth. The proliferation and apoptosis of breast cancer cells after perfusion were tested by cell viability assays, flow cytometry analysis and mRNA microarray assays. Results showed that the PVA-H microspheres efficiently absorbed the majority of VEGF (74.39%) and TGF-β (86.39%), but much less TNF-α (4.16%). The regulation of the cytokines had remarkable anti-proliferative and pro-apoptotic effects on breast cancer cells, which was further confirmed from the change of mRNA expression levels. Thus, targeting regulatory pathways within the TME by an affinity adsorbent that selectively depletes immunosuppressive cytokines is potentially a new and promising strategy for cancer therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Department of Nuclear Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China
Funding
National Key R&D Program of China · National Natural Science Foundation of China · Natural Science Foundation of Tianjin · Tianjin Science and Technology Project
References (41)
Show source-provided references
1. 10.1038/nature1575610.1038/nature15756 ↗
2. 10.1016/S1470-2045(20)30496-410.1016/S1470-2045(20)30496-4 ↗
3. 10.1016/S0002-9440(10)65392-810.1016/S0002-9440(10)65392-8 ↗
4. 10.1007/s10456-005-9010-010.1007/s10456-005-9010-0 ↗
5. 10.1186/bcr4410.1186/bcr44 ↗
6. Victor F, Gottlieb A. TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol. 2002;1(3):264–275.
7. 10.2741/315210.2741/3152 ↗
8. 10.1038/nrd138110.1038/nrd1381 ↗
9. 10.1038/nm98810.1038/nm988 ↗
10. Yamamoto Y, Ueda Y, Itoh T, et al. A novel immunotherapeutic modality with direct hemoperfusion targeting transforming growth factor-beta prolongs the survival of tumor-bearing rats. Oncol Rep. 2006;16(6):1277–1284.
11. 10.3109/21691401.2014.90982310.3109/21691401.2014.909823 ↗
12. 10.1088/1748-6041/4/6/06500710.1088/1748-6041/4/6/065007 ↗
13. 10.1007/s10856-008-3461-y10.1007/s10856-008-3461-y ↗
14. 10.1042/BSR2011007710.1042/BSR20110077 ↗
15. 10.1016/j.biomaterials.2012.01.03210.1016/j.biomaterials.2012.01.032 ↗
16. 10.3109/21691401.2016.113849410.3109/21691401.2016.1138494 ↗
17. 10.1080/21691401.2017.130440510.1080/21691401.2017.1304405 ↗
18. 10.1039/C4TB01673D10.1039/C4TB01673D ↗
19. 10.1039/C7CC02479G10.1039/C7CC02479G ↗
20. 10.1021/acsami.0c0385910.1021/acsami.0c03859 ↗
21. 10.1159/00008023510.1159/000080235 ↗
22. 10.1038/ncb340810.1038/ncb3408 ↗
23. 10.1038/nature1428210.1038/nature14282 ↗
24. 10.1016/0092-8674(92)90030-G10.1016/0092-8674(92)90030-G ↗
25. 10.1002/ijc.2634210.1002/ijc.26342 ↗
26. 10.1186/1471-2407-11-44310.1186/1471-2407-11-443 ↗
27. 10.1007/s10549-009-0503-110.1007/s10549-009-0503-1 ↗
28. 10.1074/jbc.M60199120010.1074/jbc.M601991200 ↗
29. Uría JA, Ferrando AA, Velasco G, et al. Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res. 1994;54(8):2091–2094.
30. 10.1093/carcin/bgl06710.1093/carcin/bgl067 ↗
31. 10.18632/oncoscience.6410.18632/oncoscience.64 ↗
32. 10.1158/1078-0432.CCR-07-088410.1158/1078-0432.CCR-07-0884 ↗
33. 10.1016/j.cell.2012.04.04210.1016/j.cell.2012.04.042 ↗
34. 10.1023/B:JOMG.0000037157.94207.3310.1023/B:JOMG.0000037157.94207.33 ↗
35. 10.1038/sj.onc.120093610.1038/sj.onc.1200936 ↗
36. 10.1111/j.1349-7006.2006.00146.x10.1111/j.1349-7006.2006.00146.x ↗
37. 10.1038/sj.onc.120492510.1038/sj.onc.1204925 ↗
38. 10.1080/1354570060118496310.1080/13545700601184963 ↗
39. 10.1038/onc.2012.16910.1038/onc.2012.169 ↗
40. 10.1111/j.1582-4934.2009.00938.x10.1111/j.1582-4934.2009.00938.x ↗
41. 10.1111/j.1349-7006.2008.00816.x10.1111/j.1349-7006.2008.00816.x ↗